Rates of clinically significant prostate cancer in African Americans increased significantly following the 2012 US Preventative Services Task Force recommendation against prostate specific antigen screening: A Single Institution Retrospective Study
- PMID: 31750596
- DOI: 10.1111/ijcp.13447
Rates of clinically significant prostate cancer in African Americans increased significantly following the 2012 US Preventative Services Task Force recommendation against prostate specific antigen screening: A Single Institution Retrospective Study
Abstract
Purpose: We determined the impact of the 2012 US Preventative Services Task Force recommendation against prostate specific antigen screening on detection rates and biopsy patterns in African American and Caucasian patients.
Materials and methods: Demographics, PSA, transrectal ultrasonography volume and pathologic data were collected on patients who underwent their first ultrasound-guided prostate biopsy between January 2007 and June 2018 at a New York City Veteran Affairs Hospital.
Results: 609 biopsies were analysed preguideline (113 per year), and 487 were analysed postguideline (81 per year). There was no significant difference in the detection rates of low, intermediate or high grade PCa in Caucasians. In contrast, African Americans were significantly more likely to be diagnosed with PCa in the postguideline group (56% pre vs 66% post, P = .016), and significantly more likely to be diagnosed with intermediate-high grade PCa (38% pre vs 47% post, P = .038). Before the 2012 USPSTF recommendation, African American and Caucasian patients undergoing their first biopsy were equally likely to be diagnosed with high-grade PCa (11% AA vs 11% CA). After the 2012 decision, we found that African Americans were 50% more likely than Caucasians to be diagnosed with high-grade PCa on first biopsy (10% AA vs 15% CA, P = .008).
Conclusions: In the 6 years following the 2012 USPSTF recommendation, detection rates of intermediate-high risk disease remained unchanged for Caucasian patients but have increased significantly for African Americans. The results of our study strongly support the role of routine PSA screening, particularly in higher risk patients such as African Americans.
Keywords: biopsy; early detection of cancer; government agencies; prostate-specific antigen; prostatic neoplasms.
© 2019 John Wiley & Sons Ltd.
Similar articles
-
Abrogation of survival disparity between Black and White individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation.Cancer. 2020 Dec 1;126(23):5114-5123. doi: 10.1002/cncr.33179. Epub 2020 Sep 5. Cancer. 2020. PMID: 32888321
-
Do African-American men need separate prostate cancer screening guidelines?BMC Urol. 2016 May 10;16(1):19. doi: 10.1186/s12894-016-0137-7. BMC Urol. 2016. PMID: 27165293 Free PMC article. Review.
-
African-American men with prostate cancer have larger tumor volume than Caucasian men despite no difference in serum prostate specific antigen.Can J Urol. 2018 Feb;25(1):9193-9198. Can J Urol. 2018. PMID: 29524974
-
The impact of African American race on prostate cancer detection on repeat prostate biopsy in a veteran population.Int Urol Nephrol. 2016 Dec;48(12):2015-2021. doi: 10.1007/s11255-016-1407-8. Epub 2016 Aug 31. Int Urol Nephrol. 2016. PMID: 27580731
-
Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging.Curr Opin Urol. 2017 May;27(3):205-209. doi: 10.1097/MOU.0000000000000383. Curr Opin Urol. 2017. PMID: 28221220 Review.
Cited by
-
Prostate Cancer: Community Education and Disparities in Diagnosis and Treatment.Oncologist. 2021 Jul;26(7):537-548. doi: 10.1002/onco.13749. Epub 2021 Mar 22. Oncologist. 2021. PMID: 33683758 Free PMC article.
-
Psychosocial Stress, Glucocorticoid Signaling, and Prostate Cancer Health Disparities in African American Men.Cancer Health Disparities. 2020;4:https://companyofscientists.com/index.php/chd/article/view/169/188. Cancer Health Disparities. 2020. PMID: 35252767 Free PMC article.
-
Associations of Content and Context of Communication with Prostate-Specific Antigen Testing.Int J Environ Res Public Health. 2023 May 4;20(9):5721. doi: 10.3390/ijerph20095721. Int J Environ Res Public Health. 2023. PMID: 37174239 Free PMC article.
References
REFERENCES
-
- Moyer VA. U.S. Preventive Services Task Force. Ann Intern Med. 2012;157(2):120-134.
-
- Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-1319.
-
- Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European Study. N Engl J Med. 2009;360:1320-1328.
-
- US Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:120-134.
-
- Drazer MW, Huo D, Eggener SE. National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen-based screening. J Clin Oncol. 2015;33:2416-3242.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous